Created:INDEX.md (18 canonical pages), wiki/overview.md (draft, 25 verified PMIDs), OPEN-QUESTIONS.md (7 questions), and this log.
Searches run (live PubMed E-utilities esearch/esummary): ICHD-3; GBD burden; aura, trigeminovascular/CGRP biology and genetics/GWAS; acute-treatment reviews and ubrogepant; erenumab, fremanezumab, galcanezumab, eptinezumab and rimegepant trials; PREEMPT; topiramate comparison; CBT; pediatric guidelines; stroke association; menstrual/pregnancy migraine; biomarkers and chronification.
Verification: all cited PMIDs were returned live by PubMed; one initially recalled lasmiditan identifier resolved to an unrelated back-pain paper and was excluded.
Next: full build queued per CONDITIONS-ROADMAP.md.
Built all 18 canonical wiki pages: classification/diagnosis; epidemiology/burden; trigeminovascular/CGRP biology; aura/CSD; acute and preventive treatment; chronic migraine/chronification; medication-overuse headache; neuromodulation/behavioural care; paediatrics; sex hormones/pregnancy/lactation; comorbidity/vascular risk; guidelines; biomarkers; trials; patient experience; and red flags/safety, plus the expanded overview.
Density: every wiki page is 150–400 lines. Seventeen pages carry 25–28 unique PMIDs; the trial-landscape page carries 14 PMIDs plus 39 NCT records. All pages remain status: draft pending the separately required audit session.
Literature layer: created literature/BIBLIOGRAPHY.md (375 unique papers, cited-by indexed), six structured landmark notes, guidelines/REGISTRY.md, statistics/STATISTICS.md, and the four-file patient-voice/ layer.
Research frontier: replaced seed questions with 16 stable tiered questions and a 14-row Dots not yet connected table.
PubMed searches run live: ICHD/classification; diagnostic validation, aura/TIA/seizure mimics and imaging; global/GBD and regional epidemiology; disability, productivity, family and care gaps; trigeminovascular anatomy, CGRP/PACAP provocation and sensitization; cortical spreading depolarization and visual snow; acute NSAID/triptan/gepant/ditan/DHE/antiemetic evidence; conventional, toxin, antibody and gepant prevention; chronic-migraine transition/remission and predictors; medication-overuse thresholds, withdrawal, relapse and prevention; device sham trials, CBT, biofeedback, sleep and exercise; paediatric epidemiology, CHAMP, CBT and guidelines; menstrual migraine, pregnancy, postpartum, lactation and exposure cohorts; psychiatric, sleep, epilepsy and vascular comorbidity; guideline bodies worldwide; genetic, CSF, blood, imaging and electrophysiological biomarkers; stigma, lived experience, cognition, interictal burden, work, family and access.
ClinicalTrials.gov searches run live: active and completed migraine studies, pivotal acute/preventive programs, paediatric gepants, pregnancy exposure, menstrual migraine, devices, biomarkers, combination therapy, withdrawal and strategy designs; individual study records were queried through API v2.
Verification: final live batch audit resolved 375/375 unique PMIDs through PubMed E-utilities and 39/39 unique NCT IDs through ClinicalTrials.gov API v2. Structural checks found one missing page-reference entry and three bibliography omissions; all four were corrected, then the checks were rerun.
Patient organizations: seven public sites were verified across the US, UK, Canada, Europe, Ireland and Australia. Headache Australia timed out and was quarantined rather than listed as verified.
Boundaries: no claims or identifiers were written from memory; no unresolved citation is marked as verified. No protected condition, convention, tool or frontend file was changed.
Follow-up: a separate citation audit must re-check claim-to-paper fit before any page is promoted from draft to curated; guideline currency and trial status are date-sensitive watch items.
Scope completed: audited all 18/18 wiki pages and all 16/16 literature artifacts (34 migraine Markdown artifacts total), including the 388-paper bibliography, six landmark notes, guideline registry, statistics file, patient-voice layer and open-questions register.
Live identifier verification: re-fetched 388/388 retained unique PMIDs through PubMed E-utilities and 40/40 unique NCT IDs through ClinicalTrials.gov API v2. Checked 468 page-reference occurrences and 726 in-body PMID occurrences; all retained page PMIDs are present in both the local reference list and master bibliography. No identifier was accepted from memory.
Substantive claim errors found and fixed (6): corrected the status-migrainosus review’s first-author attribution; stroke pooled-CI upper bound (1.83, not 1.82); the one-year MOH strategy interpretation (no significant between-group difference, p=0.377; 11% relapse); the limits of topiramate evidence specifically in chronic migraine with MOH; an unsupported neuromodulation tolerability comparison; and misleading candesartan crossover comparator wording.
Citation/index integrity defects found and fixed (45): attached 40 valid but previously unconnected page references to the precise claims they support; removed one valid but irrelevant placebo/psychology paper from the vascular-comorbidity page and bibliography; removed three malformed duplicate bibliography bullets; and repaired one incomplete cited by mapping. Final checks show 0 unused page references, 0 body PMIDs missing from references, 0 bibliography/page-set discrepancies and 0 duplicate retained PMIDs.
Currency and stale-absence pass: reran 12 live searches behind negative claims covering multi-class sequencing, disease modification, combination prevention, patient-weighted comparison, pregnancy exposure, predictive biomarkers, gepant/MOH liability, vascular outcomes, gepant-versus-lasmiditan comparison, pediatric infusion pathways, aura-primary endpoints and LMIC implementation. Added current evidence where found and converted remaining gaps to positively stated, dated evidence-gap sentences.
New evidence incorporated: added 14 live-verified papers, including TEMPLE (atogepant vs topiramate), comparative CGRP-antibody vascular safety, combination-prevention meta-analysis, pediatric IV-DHE and aura cohorts, a negative suPAR predictor study, and seven 2025–2026 guidelines/consensus documents. Added completed NCT05748483; the trial landscape now contains 40 live-checked registry records.
Guidelines and patient voice: expanded the master registry to 27 documents and recorded supersession/method limits through 2026. Rechecked seven public organization URLs on 2026-08-30: six returned HTTP 200; the National Headache Foundation returned HTTP 403 anti-bot; Headache Australia remained network-unreachable and is explicitly excluded rather than labelled inactive.
Final validation: all wiki pages remain within 150–400 lines and carry 25–32 unique PMIDs, except the trial-landscape page, which carries 15 PMIDs plus 40 NCT records. Relative links: 0 broken. Unverified-marker count: 0. Unresolved substantive issues: 0. Time-sensitive registry statuses and one public-site access limitation remain dated monitoring notes, not unresolved clinical claims.
Promotion: all 18 pages passed and were promoted to status: curated with last-curated: 2026-08-30; the condition roadmap was advanced to audited.
Protected scope: no git command was run and no .git/.gitignore was created. No protected condition, CONVENTIONS.md, tools/ or frontend/ file was changed.